IMMU Immunicum AB

Mendus AB: Mendus to participate in upcoming conferences in October

Mendus AB: Mendus to participate in upcoming conferences in October

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:



EDISON Oncology ABCs – Vaccines: Niche no longer

Virtual event

Mendus CMO Jeroen Rovers will participate in an expert panel webcast organized by Edison Group. Further details will be provided on the Mendus website in due time.



BIO-Europe

Leipzig, Germany, October 24-26, 2022

Mendus CEO Erik Manting and Director Business Development Céline Hechard will participate in the partnering conference.



European Society of Gynaecological Oncology 23rd Annual Conference

Berlin, Germany, October 27-30, 2022

Director Research Satwinder Kaur Singh to attend, initial data from the ALISON Phase I trial in ovarian cancer to be presented together with Mendus’ collaboration partner, the Department of Obstetrics and Gynaecology of the University Medical Centre Groningen, The Netherlands.



FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail:



INVESTOR RELATIONS

Corey Davis

LifeSci Advisors, LLC

Telephone: 7

E-mail:



MEDIA RELATIONS

Mario Brkulj

Valency Communications

Telephone: 51

E-mail:



ABOUT MENDUS AB (PUBL)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.

Attachment



EN
07/10/2022

Underlying

IMMUImmunicum AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunicum AB

Free Trial
IMMU IMMUNICUM AB

Mendus AB: 2 directors

A director at Mendus AB bought 17,842 shares at 7.566SEK and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

07/22/25 July 22, 2025 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Collaboration unveils path forward for ilixadencel

Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer centre in France, to test ilixadencel in soft tissue sarcomas (STS) as part of an ongoing Phase I/II basket trial (REGOMUNE). The trial is a multi-centre, prospective open-label study assessing the combination of regorafenib (a tyrosine kinase inhibitor) and avelumab (an immune checkpoint inhibitor) in various solid tumours. Ilixadencel will be evaluated along with a combination in one of the treatme...

07/24/24 July 24, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Recent clinical data highlight vididencel’s potential

Mendus recently presented positive data from two ongoing clinical studies, ADVANCE II and ALISON, at the EHA and ESMO conferences, respectively. While the Phase I ALISON trial, evaluating lead asset vididencel in ovarian cancer, met its primary endpoint of generating sufficient vaccine-induced responses (VIR), further analysis of ADVANCE II data (studying vididencel as a maintenance therapy in AML) confirmed the drug’s potential in generating a broader immune response through both T-cell and B-c...

06/21/24 June 21, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - All hands on deck as inflection points approach

With Mendus’s Q124 results, management recapped its clinical priorities, which are all progressing as expected. The focus remains on the AMLM22-CADENCE trial for lead cancer vaccine vididencel, in combination with oral azacitidine as a maintenance treatment for acute myeloid leukaemia (AML). R&D expenses came in slightly ahead of expectations with the ramp up in clinical activity, including preparation for the subsequent pivotal Phase III trial, with large-scale manufacturing of vididencel (plan...

05/20/24 May 20, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Gross proceeds of c SEK69m to advance pipeline

Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were issued in connection with the July 2023 raise of SEK317m. Management anticipates that these proceeds will extend the cash runway to Q325 and will be applied to progress its clinical pipeline, mainly in preparation for a registrational trial for lead cancer vaccine vididencel, targeting acute myeloid leukaemia (AML) in the maintenance setting. Management expects the registrational study to commence...

04/04/24 April 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch